A Prospective Study of PD-1 Inhibitor Combined With ICE in the Treatment of Relapsed/Refractory Gray Area Lymphoma

NCT04860674 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Gray Zone Lymphoma
Relapse/Recurrence
Chemotherapy Effect

Interventions

DRUG: PD-1 inhibitor +ICE

Sponsor

Zhejiang Cancer Hospital